Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Hernia Mesh Lawsuit Filed on Behalf of Ethicon Physiomesh Patient Scheduled for January 2018 Trial, Bernstein Liebhard LLP Reports

Bernstein Liebhard
Posted on: 30 Sep 16

NEW YORK, Sept. 30, 2016 /PRNewswire/ -- A hernia mesh lawsuit (http://www.rxinjuryhelp.com/ethicon-physiomesh/lawsuit/) filed on behalf of a patient who received Ethicon, Inc.'s Physiomesh Flexible Composite Mesh to repair an abdominal wall hernia is scheduled to go to trial in January 2018. A docket entry posted by the U.S. District Court, Southern District of Illinois, indicates that the Physiomesh lawsuit has been assigned to an 18-month track, with the trial to commence on January 22, 2018. (Case No. 3:16-cv-00368-JPG-PMF)

According to a complaint dated April 1, 2016, the Plaintiff underwent hernia surgery with the Physiomesh device in 2013. He began experiencing severe abdominal pain, chills and redness on the skin of his abdomen in July 2015. After being hospitalized, it was found that his hernia mesh had become infected, resulting in two abdominal abscesses and an intestinal fistula. The plaintiff, who was forced to undergo surgery to debride the abscesses, claims that the Physiomesh device used in his hernia surgery was defective, unreasonably dangerous and not suitable for its intended use.

"This Physiomesh product was voluntarily withdrawn from the global market in May, due to high rates of hernia recurrence and revision in patients who had undergone laparoscopic ventral hernia repair. Our Firm has heard from a number of individuals who have experienced similar complications allegedly due to this hernia mesh, and we are monitoring the progress of this lawsuit very closely," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is now evaluating hernia mesh lawsuits involving injuries and complications allegedly related to Ethicon's Physiomesh Flexible Composite Mesh.

Physiomesh Market Withdrawal

Ethicon Physiomesh Flexible Composite Mesh is an implantable tissue-separating mesh designed to be physiologically compatible with the abdominal wall. It is manufactured from flexible, non-absorbable polypropylene (plastic) filaments that are woven into fabric and laminated. Physiomesh Flexible Composite Mesh was cleared by the U.S. Food & Drug Administration (FDA) in 2010, via the agency's 510K program. This program does not require a device manufacturer to conduct human clinical trials, as long as it can be demonstrated that the new product is substantially equivalent to another device that was previously approved by the FDA.

Ethicon announced the worldwide market withdrawal of Physiomesh Flexible Composite Mesh on May 25, 2016. According to the company, unpublished data from two European registries indicated the recurrence and revision rates following laparoscopic ventral hernia pair were higher with the device than rates associated with the comparator set of mesh. Ethicon was unable to determine the cause of this issue, but noted that it could be due to product characteristics, as well as operative and patient factors. According to the company's notification, Physiomesh Flexible Composite Mesh will not be returned to the market.

Bernstein Liebhard LLP is offering free, no-obligation legal reviews to patients who experienced serious complications following hernia repair with Physiomesh Flexible Composite Mesh. To learn more about filing a hernia mesh lawsuit, please visit Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's "Plaintiffs' Hot List," recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2016 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.rxinjuryhelp.com/
https://plus.google.com/115936073311125306742?rel=author

For more information:
www.bernlieb.com

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 30/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.